NASDAQ:ORGO Organogenesis Q3 2025 Earnings Report $4.04 -0.09 (-2.18%) Closing price 04:00 PM EasternExtended Trading$4.00 -0.04 (-0.89%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Organogenesis EPS ResultsActual EPSN/AConsensus EPS $0.07Beat/MissN/AOne Year Ago EPSN/AOrganogenesis Revenue ResultsActual RevenueN/AExpected Revenue$134.10 millionBeat/MissN/AYoY Revenue GrowthN/AOrganogenesis Announcement DetailsQuarterQ3 2025Date11/6/2025TimeAfter Market ClosesConference Call DateThursday, November 6, 2025Conference Call Time5:00PM ETConference Call ResourcesEarnings HistoryCompany Profile Organogenesis Earnings HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Organogenesis Holdings Inc. - ORGOOctober 8 at 4:36 PM | prnewswire.comOrganogenesis Holdings Inc. to Report Third Quarter of Fiscal Year 2025 Financial Results on November 6, 2025October 1, 2025 | globenewswire.comNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $25 trillion AI revolution — one that Nvidia’s CEO himself has called a “multi-trillion-dollar future industry” — and he’s uncovered a little-known stock 168 times smaller than Nvidia that could be positioned to ride this breakthrough.October 9 at 2:00 AM | Brownstone Research (Ad)Organogenesis: Mixed ReNu Data, But Policy Tailwinds And Growth Remain BullishSeptember 29, 2025 | seekingalpha.comWhy Is Organogenesis Stock Trading Lower Friday?September 26, 2025 | benzinga.comBuy Rating for Organogenesis Holdings Despite Mixed Trial Results, Supported by Diversified Revenue and FDA Clearance EffortsSeptember 26, 2025 | tipranks.comSee More Organogenesis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Organogenesis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Organogenesis and other key companies, straight to your email. Email Address About OrganogenesisOrganogenesis (NASDAQ:ORGO) Inc. operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers. Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures. These products are supported by clinical data demonstrating efficacy in accelerating wound closure and improving patient outcomes in both inpatient and outpatient settings. Headquartered in Canton, Massachusetts, Organogenesis maintains manufacturing and distribution capabilities in North America with a network of clinical and commercial operations aimed at expanding access to advanced wound care and regenerative therapies. The company continues to invest in research and development to broaden its product pipeline and pursue collaborations that enhance its position in the global regenerative medicine market.View Organogenesis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)BlackRock (10/14/2025)Citigroup (10/14/2025)The Goldman Sachs Group (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)Wells Fargo & Company (10/14/2025)ASML (10/15/2025)Abbott Laboratories (10/15/2025)Bank of America (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
